Basilea Pharmaceutica Ltd. has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting gram-negative bacteria, including multidrug-resistant strains.
Researchers from Yangzhou University presented the discovery and preclinical characterization of LysZX4-NCA, a new endolysin therapeutic being developed for the treatment of multidrug-resistant highly virulent Klebsiella pneumoniae (MDR-hvKP) infections.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
Phaxiam Therapeutics SA has initiated a new preclinical development program targeting Klebsiella pneumoniae, which is responsible for severe infections and notable for its high resistance to antibiotics.
A Taiwanese study has demonstrated that human placental mesenchymal stem cells were therapeutic in hypervirulent Klebsiella pneumonia intra-abdominal infections by secreting IL-1beta to augment neutrophil numbers and functions, while restraining immune responses by other leukocytes.